IRLAB A Stock Overview
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson’s disease and other CNS disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
IRLAB Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 14.70 |
| 52 Week High | SEK 20.20 |
| 52 Week Low | SEK 8.72 |
| Beta | 0.76 |
| 1 Month Change | -4.23% |
| 3 Month Change | 12.21% |
| 1 Year Change | 2.44% |
| 3 Year Change | -54.98% |
| 5 Year Change | -44.63% |
| Change since IPO | 24.58% |
Recent News & Updates
Recent updates
Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?
Oct 30
IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?
Jun 06Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation
Jan 04Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely
Sep 21We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully
Mar 18IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans
Dec 01We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit
May 19We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Sep 11We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Apr 30What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Mar 19We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth
Jan 25Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay
Dec 21What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Nov 25
Shareholder Returns
| IRLAB A | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 7.7% | 5.2% | -0.7% |
| 1Y | 2.4% | 17.3% | 12.1% |
Return vs Industry: IRLAB A underperformed the Swedish Pharmaceuticals industry which returned 19.8% over the past year.
Return vs Market: IRLAB A underperformed the Swedish Market which returned 12.8% over the past year.
Price Volatility
| IRLAB A volatility | |
|---|---|
| IRLAB A Average Weekly Movement | 13.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: IRLAB A's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IRLAB A's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 31 | Kristina Torfgard | www.irlab.se |
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson’s disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms of Parkinson’s disease. Its preclinical stage products include IRL942 research programs for the treatment of cognitive deficits in Parkinson’s and other neurological disorders; IRL757 to treat apathy in neurological diseases; and IRL1117, a drug candidate developed oral treatment for the hallmark symptoms of Parkinson’s.
IRLAB Therapeutics AB (publ) Fundamentals Summary
| IRLAB A fundamental statistics | |
|---|---|
| Market cap | SEK 762.47m |
| Earnings (TTM) | -SEK 83.13m |
| Revenue (TTM) | SEK 94.63m |
8.1x
P/S Ratio-9.2x
P/E RatioIs IRLAB A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRLAB A income statement (TTM) | |
|---|---|
| Revenue | SEK 94.63m |
| Cost of Revenue | SEK 136.29m |
| Gross Profit | -SEK 41.66m |
| Other Expenses | SEK 41.47m |
| Earnings | -SEK 83.13m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 21, 2025
| Earnings per share (EPS) | -1.60 |
| Gross Margin | -44.03% |
| Net Profit Margin | -87.85% |
| Debt/Equity Ratio | 163.8% |
How did IRLAB A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 00:22 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IRLAB Therapeutics AB (publ) is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Gonzalo Artiach Castanon | ABG Sundal Collier Sponsored |
| null null | ABG Sundal Collier Sponsored |